Revolution Medicines Inc. Common Stock (RVMD)
Stock · NASDAQ · Health Care
$178.07as of 10/16/2026
Price chart
Active signals
RVMD Signal Track Record
How signals performed across all stocks →What RVMD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | +3.4% | 68% | October 8, 2026 |
| Bollinger Band Breakout | 31 | +3.2% | 55% | August 5, 2026 |
| Bollinger Band BreakdownActive now | 15 | +2.6% | 80% | September 16, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -0.4% | 46% | September 5, 2025 |
| Any 20-session window (baseline) | +4.9% | 63% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to s…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 883
- Website
- www.revmed.com/
Fundamentals
- 1-day range
- $175.91$189.68
- Market cap
- $42.05B
- P/E (trailing)
- —
- P/E (forward)
- -30.52
- EPS (trailing)
- $-4.80
- Dividend yield
- —
- Beta
- 1.42
- Avg. volume
- 1.95M
How Revolution Medicines Inc. Common Stock Makes Money
Where the revenue actually goes — FY2022 annual results
Source: 10-K filed Feb 27, 2023 · via SEC EDGAR / Finnhub
Forecasts
24 analyst ratings
Revolution Medicines Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- RVMDRevolution Medicines Inc. Common Stock$177.96▼ 5.97%Market cap $42.05BP/E —$47.45$224.31
- BIIBBiogen Inc. Common Stock$232.65▼ 1.15%Market cap $30.48BP/E 42.27$138$238.24
- ARGXargenx SE American Depositary Shares$819.14▼ 3.21%Market cap $54.32BP/E 21.26$568.4$925
- BNTXBioNTech SE American Depositary Share$87.71▼ 2.76%Market cap $22.91BP/E —$79.52$124
- MRNAModerna Inc. Common Stock$218.01▼ 7.82%Market cap $21.50BP/E —$22.28$227.46
- NBIXNeurocrine Biosciences Inc. Common Stock$135.71▼ 0.91%Market cap $16.25BP/E 19.57$122.14$186.12
- EXELExelixis Inc. Common Stock$62.23▼ 0.95%Market cap $13.12BP/E 17.49$33.76$61.66
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RVMD Revolution Medicines Inc. Common Stock | $42.05B | — | $177.96 | ▼ 5.97% | $47.45$224.31 |
| BIIB Biogen Inc. Common Stock | $30.48B | 42.27 | $232.65 | ▼ 1.15% | $138$238.24 |
| ARGX argenx SE American Depositary Shares | $54.32B | 21.26 | $819.14 | ▼ 3.21% | $568.4$925 |
| BNTX BioNTech SE American Depositary Share | $22.91B | — | $87.71 | ▼ 2.76% | $79.52$124 |
| MRNA Moderna Inc. Common Stock | $21.50B | — | $218.01 | ▼ 7.82% | $22.28$227.46 |
| NBIX Neurocrine Biosciences Inc. Common Stock | $16.25B | 19.57 | $135.71 | ▼ 0.91% | $122.14$186.12 |
| EXEL Exelixis Inc. Common Stock | $13.12B | 17.49 | $62.23 | ▼ 0.95% | $33.76$61.66 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Growbenzinga · 10/16/2026
- FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analystsYahoo · 10/9/2026
- Stock Market Today: S&P 500 Slips as Oil Spikes 5%, 10-Year Yields Near 5.35%Benzinga · 10/8/2026
- Adlai Nortye Group: Only For The Risk-Tolerant After A Massive RallySeekingAlpha · 10/8/2026
- RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $259Benzinga · 10/8/2026
- Revolution Medicines CEO on Defeating the RAS GeneYahoo · 10/7/2026
- Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $240Benzinga · 10/7/2026
- First-Line RAS G12D Pancreatic Cancer Trial Launch Could Be A Game Changer For Revolution Medicines (RVMD)Yahoo · 10/7/2026
- Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest LosersYahoo · 10/6/2026
Insider Activity
Insider Actions →- Sandler Alan B. · September 29, 2026 · Option Exercise6.0K @ $58.84
- Sandler Alan B. · September 29, 2026 · Sale301 @ $204.72
- Sandler Alan B. · September 29, 2026 · Sale1.2K @ $203.91
- Sandler Alan B. · September 29, 2026 · Sale1.0K @ $202.81
- Sandler Alan B. · September 29, 2026 · Sale1.6K @ $201.72
- Sandler Alan B. · September 29, 2026 · Sale2.2K @ $200.82
- Jeff Cislini · September 25, 2026 · Sale765 @ $207.32
- Anthony Mancini · September 25, 2026 · Option Exercise3.1K @ $33.62
- Anthony Mancini · September 25, 2026 · Sale3.1K @ $200.54
- Anthony Mancini · September 24, 2026 · Sale587 @ $200
- Elizabeth M. Anderson · September 22, 2026 · Sale2.6K @ $193.44
- Elizabeth M. Anderson · September 22, 2026 · Sale5.0K @ $192.54
- Elizabeth M. Anderson · September 22, 2026 · Sale910 @ $191.85
- Elizabeth M. Anderson · September 22, 2026 · Option Exercise5.1K @ $1.12
- Elizabeth M. Anderson · September 22, 2026 · Sale100 @ $195.15
Institutional Ownership
March 31, 2026
- Total shares held
- 197.06M
- Total value held
- $18.44B
- Institutional holders
- 507
- Unknown13.60M
- Unknown11.21M
- Unknown9.77M
- Unknown9.56M
- Unknown8.46M
- Unknown8.36M
- Unknown7.60M
- Unknown6.66M
- Unknown6.03M
- Unknown5.48M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
RVMD RASONQUE Receives Positive EU CHMP Opinion
The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization for Revolution Medicines’ RASONQUE (daraxonrasib) in metastatic pancreatic cancer. This development supports the company’s pipeline and may broaden its commercial prospects in Europe. Analysts have maintained their target price, reflecting confidence in the drug’s potential.
RVMD RASONQUE Receives Positive EU CHMP Opinion. The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization for Revolution Medicines’ RASONQUE (daraxonrasib) in metastatic pancreatic cancer. This development supports the company’s pipeline and may broaden its commercial prospects in Europe. Analysts have maintained their target price, reflecting confidence in the drug’s potential.